1194 related articles for article (PubMed ID: 32117298)
1. NK Cell-Based Immune Checkpoint Inhibition.
Khan M; Arooj S; Wang H
Front Immunol; 2020; 11():167. PubMed ID: 32117298
[TBL] [Abstract][Full Text] [Related]
2. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
3. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C; Liu Y
Front Immunol; 2020; 11():1295. PubMed ID: 32714324
[TBL] [Abstract][Full Text] [Related]
4. Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.
Alfarra H; Weir J; Grieve S; Reiman T
Front Immunol; 2020; 11():575609. PubMed ID: 33304346
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
6. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
8. NK Cell Dysfunction and Checkpoint Immunotherapy.
Bi J; Tian Z
Front Immunol; 2019; 10():1999. PubMed ID: 31552017
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer.
Buckle I; Guillerey C
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503073
[TBL] [Abstract][Full Text] [Related]
10. Control of NK Cell Activation by Immune Checkpoint Molecules.
Beldi-Ferchiou A; Caillat-Zucman S
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29023417
[TBL] [Abstract][Full Text] [Related]
11. The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.
Sun H; Sun C
Front Immunol; 2019; 10():2354. PubMed ID: 31681269
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
Cao Y; Wang X; Jin T; Tian Y; Dai C; Widarma C; Song R; Xu F
Signal Transduct Target Ther; 2020 Oct; 5(1):250. PubMed ID: 33122640
[TBL] [Abstract][Full Text] [Related]
13. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.
Sivori S; Vacca P; Del Zotto G; Munari E; Mingari MC; Moretta L
Cell Mol Immunol; 2019 May; 16(5):430-441. PubMed ID: 30778167
[TBL] [Abstract][Full Text] [Related]
14. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
Cifaldi L; Di Santo J; Olive D
Front Immunol; 2020; 11():1132. PubMed ID: 32612604
[No Abstract] [Full Text] [Related]
15. PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.
Pesce S; Greppi M; Grossi F; Del Zotto G; Moretta L; Sivori S; Genova C; Marcenaro E
Front Immunol; 2019; 10():1242. PubMed ID: 31214193
[TBL] [Abstract][Full Text] [Related]
16. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.
Alemohammad H; Najafzadeh B; Asadzadeh Z; Baghbanzadeh A; Ghorbaninezhad F; Najafzadeh A; Safarpour H; Bernardini R; Brunetti O; Sonnessa M; Fasano R; Silvestris N; Baradaran B
Biomed Pharmacother; 2022 Feb; 146():112516. PubMed ID: 34906767
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer.
Sivori S; Della Chiesa M; Carlomagno S; Quatrini L; Munari E; Vacca P; Tumino N; Mariotti FR; Mingari MC; Pende D; Moretta L
Front Immunol; 2020; 11():2156. PubMed ID: 33013909
[TBL] [Abstract][Full Text] [Related]
18. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
19. Emerging targets in cancer immunotherapy.
Burugu S; Dancsok AR; Nielsen TO
Semin Cancer Biol; 2018 Oct; 52(Pt 2):39-52. PubMed ID: 28987965
[TBL] [Abstract][Full Text] [Related]
20. Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?
Lentz RW; Colton MD; Mitra SS; Messersmith WA
Mol Cancer Ther; 2021 Jun; 20(6):961-974. PubMed ID: 33850005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
